Summary
Asklepios Biopharmaceutical operates as a AAV gene therapy company. The Company offers end-to-end gene therapy platform includes scaled-up manufacturing with its Pro10 cell line, AAV capsid library, and clinical programs for a range of genetic disease indications. Asklepios Biopharmaceutical serves customers in the State of North Carolina.
Deals Overview
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.
Senior Management
Sheila Ann Mikhail
CEO
Tim Trost
CFO
Richard Jude Samulski
Chief Scientific Officer and Co-Founder
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy